Frazier Life Sciences Management, L.P. Trevi Therapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.67 Billion
- Q4 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 10,664,774 shares of TRVI stock, worth $52.2 Million. This represents 2.72% of its overall portfolio holdings.
Number of Shares
10,664,774
Previous 7,381,090
44.49%
Holding current value
$52.2 Million
Previous $24.7 Million
84.29%
% of portfolio
2.72%
Previous 1.33%
Shares
6 transactions
Others Institutions Holding TRVI
# of Institutions
114Shares Held
77.6MCall Options Held
218KPut Options Held
182K-
Nea Management Company, LLC Timonium, MD11.4MShares$55.6 Million3.46% of portfolio
-
Viking Global Investors LP4.4MShares$21.5 Million0.06% of portfolio
-
Rubric Capital Management LP New York, NY4.21MShares$20.6 Million0.3% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.15MShares$20.3 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.51MShares$17.2 Million0.0% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $285M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...